MEI Pharma

MEI Pharma, a San Diego-based clinical-stage pharmaceutical company, is dedicated to developing and commercializing novel, best-in-class cancer therapies with the aim of improving patient outcomes. The company's approach involves understanding and leveraging the mechanisms and properties of its drug candidates to optimize the balance between efficacy and tolerability, meeting the specific needs of cancer patients. Each pipeline candidate possesses a unique mechanism of action targeting pathways involved in various hematological malignancies and solid tumors. One of MEI Pharma's key pipeline candidates is Zandelisib (formerly known as ME-401), which is undergoing multiple clinical trials to evaluate its effectiveness in patients with B-cell malignancies, with the intention to support marketing approvals from the FDA and other regulatory authorities globally. Additionally, Voruciclib, a potent inhibitor of CDK9, is being explored in combination with standard therapies for the treatment of hematologic malignances and solid tumors. Another promising drug candidate is ME-344, a mitochondrial inhibitor being evaluated for the treatment of solid tumors. Founded in 2000, MEI Pharma focuses on Biopharma and Biotechnology industries. The company secured a significant investment of $51.75M in Post-IPO Equity at 19 December 2019. MEI Pharma upholds its dedication to its mission and workplace values, including dedication, shared commitment, personal accountability, mutual trust, and fiscal discipline. For individuals interested in joining a team of friendly, dedicated, experienced, and collaborative professionals, more details can be found at meipharma.com/careers.